| answer text |
<p><ins class="ministerial"> <p><ins class="ministerial">The Department for International
Trade and the Department of Health and Social Care are not specifically collecting
data on the growth of the market for cannabis based products for medicinal use in
the United Kingdom.</ins></p><p><ins class="ministerial">However, data from the Medicines
and Healthcare products Regulatory Agency (MHRA) shows growing numbers of import notifications
for medicinal cannabis and the Home Office has received increased numbers of licence
applications.</ins></p><p><ins class="ministerial">In addition, UK companies exporting
these products and foreign companies looking to invest in the UK have full access
to government support, where they have the necessary authorisations from the MHRA
and Home Office and a relevant Export Licence.</ins></p></ins></p><p><del class="ministerial">An
initial impact assessment was published alongside The Misuse of Drugs (Amendments)
(Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. This can
be viewed at the following link:</del></p><p><del class="ministerial"><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts"
target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></del></p><p><del
class="ministerial">This set out the approach that the Government proposed to take
in assessing the costs and benefits of the change in the law at a population level,
with regard to the rescheduling of cannabis-based products for medicinal use (CBPM).
This framework included potential savings in treatment costs, giving the example of
patients with severe epilepsy for whom medicinal use of cannabis could reduce the
frequency of seizures and reduce the number of related hospital admissions. This was
an initial framework for assessing this policy and as we develop our knowledge in
this area, both on the costs and the potential benefits, we can revisit and refine
these assessments.</del></p><p><del class="ministerial">In the meantime, the National
Institute for Health and Care Excellence (NICE) is developing clinical guidelines
on the appropriate use of CBPM based on the best available evidence, and the National
Institute for Health Research is funding further clinical research on this. More information
is available at the following link:</del></p><p><del class="ministerial"><a href="https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf"
target="_blank">https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf</a></del></p>
|
|
